ALDH9A1: Unlocking The Potential Therapeutic Targets and Biomarkers

Target Name: ALDH9A1

NCBI ID: G223

ALDH9A1

ALDH9A1: Unlocking The Potential Therapeutic Targets and Biomarkers

ALDH9A1 (also known as OTTHUMP00000032604) is a protein that is expressed in the liver and other tissues in the body. It is a member of the alkaline phosphatase gene family (APG) and is involved in a variety of cellular processes, including metabolism, energy production, and signaling.

One of the unique features of ALDH9A1 is its role in the regulation of cellular energy metabolism. In addition to its role in generating ATP, ALDH9A1 is also involved in the breakdown of fatty acids and the production of ceramide, which is a key signaling molecule in the immune system.

Another important function of ALDH9A1 is its role in the regulation of cellular signaling. It is a potent inhibitor of the protein kinase PDK4, which is involved in a variety of cellular processes, including cell growth, differentiation, and survival. This means that when ALDH9A1 is present in cells, it can inhibit the activity of PDK4 and prevent it from leading to the breakdown of cellular signaling pathways.

In addition to its role in cellular signaling, ALDH9A1 is also involved in the regulation of cellular waste removal. It is a critical enzyme in the detoxification of xenobiotics, which are harmful substances that can be found in the environment and in our bodies. This means that ALDH9A1 plays a key role in ensuring that these harmful substances are removed from the body and are not harmful to our health.

Despite its many important functions, ALDH9A1 is not yet a well-established drug target or biomarker. This is because while it is involved in a variety of cellular processes that are important for human health, it is not a specific protein that is targeted by drugs or used as a biomarker in disease diagnostic tools.

However, the potential importance of ALDH9A1 as a drug target or biomarker is an area of ongoing research. Researchers are interested in understanding more about the role of ALDH9A1 in cellular signaling and how it might be targeted by drugs. This information could be useful in the development of new treatments for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

In conclusion, ALDH9A1 is a protein that is expressed in the liver and other tissues in the body that is involved in a variety of cellular processes, including energy metabolism, signaling, and waste removal. While it is not yet a well-established drug target or biomarker, the potential importance of ALDH9A1 as a potential therapeutic target or biomarker is an area of ongoing research that could lead to new treatments for a variety of diseases.

Protein Name: Aldehyde Dehydrogenase 9 Family Member A1

Functions: Converts gamma-trimethylaminobutyraldehyde into gamma-butyrobetaine with high efficiency (in vitro). Can catalyze the irreversible oxidation of a broad range of aldehydes to the corresponding acids in an NAD-dependent reaction, but with low efficiency

The "ALDH9A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDH9A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets